Table 6.

Office blood pressure at the end of the baseline period and at 5 weeks after randomization

		Mean level ± SD at end of period		Mean differences (95% CI)		P-value
	N	Baseline	5 weeks	5 weeks minus baseline	Double difference (rostafuroxin minus placebo)
Systolic pressure, mm Hg
Placebo	203	149.8 ± 7.2	144.5 ± 12.5	-5.35 (-6.97 to -3.74)
Rostafuroxin
0.05 mg	42	150.5 ± 7.3	144.5 ± 12.6	-6.00 (-9.86 to -2.13)	-1.20 (-6.28 to 3.87)	0.64
0.15 mg	40	150.5 ± 8.4	143.9 ± 12.4	-6.60 (-9.91 to -3.29)	-3.08 (-8.03 to 1.88)	0.22
0.5 mg	40	153.0 ± 8.7	147.4 ± 11.5	-5.65 (-9.42 to -1.88)	0.96 (-4.74 to 6.66)	0.74
1.5 mg	43	151.0 ± 7.9	147.4 ± 15.2	-3.68 (-7.87 to 0.51)	1.59 (-3.77 to 6.95)	0.56
5.0 mg	42	149.6 ± 7.1	145.3 ± 14.0	-4.31 (-8.55 to -0.07)	2.45 (-3.05 to 7.95)	0.38
All doses	207	150.9 ± 7.9	145.7 ± 13.2	-5.22 (-6.92 to -3.53)	0.13 (-2.21 to 2.47)	0.91
Diastolic pressure, mm Hg
Placebo	203	92.0 ± 7.2	89.4 ± 8.7	-2.63 (-3.77 to -1.50)
Rostafuroxin
0.05 mg	42	92.9 ± 7.2	89.9 ± 8.3	-3.01 (-4.90 to -1.11)	0.52 (-2.65 to 3.70)	0.75
0.15 mg	40	92.3 ± 7.5	88.5 ± 8.5	-3.82 (-6.12 to -1.51)	-1.94 (-5.52 to 1.65)	0.28
0.5 mg	40	95.9 ± 6.6	92.0 ± 7.8	-3.96 (-6.67 to -1.25)	-1.20 (-5.32 to 2.92)	0.56
1.5 mg	43	94.2 ± 8.3	92.9 ± 9.4	-1.33 (-3.77 to 1.12)	-0.21 (-3.26 to 2.84)	0.89
5.0 mg	42	94.0 ± 6.5	90.7 ± 9.2	-3.33 (-6.32 to -0.35)	0.68 (-3.15 to 4.51)	0.72
All doses	207	93.9 ± 7.3	90.8 ± 8.7	-3.06 (-4.15 to -1.98)	-0.43 (-2.00 to 1.13)	0.59

Mean differences were estimated with a paired and unpaired t-tests for within-group and between-group differences, respectively. The double difference is the net treatment effect defined as the difference placebo minus baseline subtracted from the difference rostafuroxin minus baseline (parallel-group analysis). Abbreviations: N = number of patients; SD, standard deviation; CI, confidence interval.